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HIV is not indicated in the aetiology of Castleman’s disease. However, it impacts on the prevalence and natural history of 
this disease and signi cantly on the disease progression. Castleman’s disease is a uni- or multicentric disease of the lymph 
node with or without polyclonal proliferation of B-cells. It is a morphologically distinct form of lymph node hyperplasia 
and is characterised by signi cant architectural changes in all lymphatic compartments. Histopathologically, the disease is 
classi ed into two major subtypes: the hyaline-vascular type and the plasma-cell type. A mixed type is also identi ed, as there 
are frequent transitions between the types.  e diagnosis of Castleman’s disease needs to be made histologically. Treatment 
modalities include surgery, which is curative for unicentric disease, and systemic therapy, which is needed for multicentric 
disease.  is case highlights the diagnostic value of lymph node excision biopsy in HIV-infected patients. 
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A 49-year-old male patient presented to our 
emergency department with a 5-day history 
of a non-productive cough, fever, chills, 
shortness of breath and lower abdominal pain 
with associated nausea and vomiting. His 
background history was that of longstanding diabetes mellitus 
and hypertension, but he did not report an HIV diagnosis 
or antiretroviral use. Upon examination, the patient did not 
appear chronically ill. His vitals included a blood pressure 
of 163/73 mmHg, a respiratory rate of 25 breaths per minute 
and a temperature of 37.5°C. Generalised lymphadenopathy 
was also detected, especially in the cervical and right axillary 
areas.  e lymph nodes were hard, non-tender, mobile and 
measured 1 - 2 cm in diameter. Examination of the heart and 
lungs revealed no abnormalities. Palpation of the abdomen 
con rmed splenomegaly, suprapubic tenderness and right renal 
angle tenderness. 
Abnormal laboratory findings included haematuria, 
haemoglobin at 9.2 g/dl (normal range 14.3 - 18.3 g/dl), and 
microscopic examination of the urine-cultured Klebsiella. An 
HIV enzyme-linked immunosorbent assay was positive, and 
the initial CD4+ was 233 × 106/l. Three specimens of nasogastric 
aspirates were negative for tuberculosis. A lymph node biopsy 
was done and the histological findings confirmed features 
that were in keeping with early human herpesvirus type 8 
(HHV- 8)-associated multicentric Castleman’s disease. Also 
present was predominantly sinusoidal vascular proliferation in 
keeping with Kaposi’s sarcoma. In addition, the surrounding 
lymphoid tissue showed against the background of what 
appeared to be preceding follicular hyperplasia features of 
marked folliculolysis, and increased plasmacytoid cells and 
plasma cells were also seen populating some of the follicles. 
Other features of Castleman’s disease included the ‘onion skin’ 
arrangement of the surrounding lymphocyte (Fig. 1). 
Discussion
Multicentric Castleman’s disease (MCD) is an uncommon, 
aggressive lymphoproliferative disorder with an increased 
prevalence in people living with HIV.[1] It was  rst described in 
a case report by Castleman and Towne in 1954.[2] Classi cation 
of disease types is based on histopathological features, and two 
major subtypes are identi ed: the hyaline-vascular type and the 
plasma-cell type. A mixed type is also identi ed, as there are 
frequent transitions between the two types.[3] Based on clinical 
features, Castleman’s disease can be divided into solitary and 
multicentric types. Common sites for the solitary type are in 
the mediastinum, neck, lung, mesentery, axillary lymph nodes, 
Fig. 1. Histology reveals small lymphocytes arranged in a concentric 


















peritoneum, so tissues and nasopharynx, where a mass forms. e 
dominant histopathological type, in over 90% of cases of the solitary type, 
is the hyaline-vascular type. e plasma-cell type is found mostly in the 
multicentric or systemic form of the disease. In the hyaline-vascular type, 
aected lymph nodes are characterised by follicular and interfollicular 
vascular proliferation. A wide variety of follicle sizes have been identied, 
and most of them contain small hyalinised blood vessels that penetrate the 
germinal centres in an outward concentric fashion from the perifollicular 
area, giving it the characteristic appearance shown in Fig. 1. Numerous 
capillaries and cells, especially lymphocytes, admix with some plasma 
cells, and in rare cases, immunoblasts ll the interfollicular areas. In 
contrast, in the plasma-cell type, the main features are sheets of plasma 
cells with large and hyperplastic follicles.[4]
In a study by O’Leary et al.,[5] researchers looked at 16 patients with 
Castleman’s disease and examined the correlation between HHV-8 and 
Castleman’s disease lymph node angiogenesis. Of the study sample, 
five MCD and two solitary Castleman’s disease biopsies were positive 
for HHV-8. This represented 43% of the patients, a small proportion 
that may suggest a reactivation of latent HHV-8 infection in patients 
with Castleman’s disease. Detailed analysis confirmed that HHV-8 was 
identified in 10% of the B-lymphocytes in the endothelial cells and 
in subcapsular spindle cell proliferations. A mechanism implicated 
in the pathogenesis of angiogenesis in Castleman’s disease is via the 
production of HHV-8 viral interleukin 6 (IL-6).[5]
To facilitate risk stratification, prognosis and choice of treatment, 
staging of the disease is recommended. Three crucial aspects need 
to be addressed: (i) extent of the disease, which can be evaluated by 
imaging; (ii) the histopathological classification, as this has implications 
regarding therapy; and (iii) viral aetiology, determined by blood 
tests to clarify HIV status, serology to establish presence of Epstein-
Barr virus, and immunostaining to detect viral IL-6.[3] Even though 
clinical presentation is usually nonspecific, symptoms fall into four 
categories: (i) local compression effects caused by enlarged lymph 
nodes; (ii) systemic symptoms such as fever, weight loss, night sweats, 
weakness and fatigue caused by B-cell involvement and related cytokine 
activation; (iii) fluid retention-associated symptoms such as oedema, 
ascites and pleural effusion; and (iv) clinical features as a result of 
associated complication, e.g. lymphoma.[3] As a general rule, when 
local compression symptoms are present, it is likely to be unicentric 
hyaline-vascular Castleman’s disease, while when systemic symptoms 
are present, multicentric plasma-cell type should be considered. 
Specific clinical parameters have been identified by Oksenhendler[6] 
to increase the rate of diagnosing Castleman’s disease in HIV-positive 
individuals, including fever, diffuse lymphadenopathy, splenomegaly, 
severe cytopenia, high serum C-reactive protein levels, elevated 
HHV-8 DNA levels in peripheral blood mononuclear cells, extreme 
plasmacytosis in lymph nodes or bone marrow, nasal obstruction, 
respiratory symptoms, Kaposi’s sarcoma lesions, a previous similar 
episode with spontaneous resolution, positive Coombs’ test and 
haemophagocytic syndrome. Castleman’s disease is also associated with 
Kaposi’s sarcoma, non-Hodgkin lymphoma, paraneoplastic pemphigus 
and POEMS syndrome (peripheral neuropathy, organomegaly, 
endocrinopathy, monoclonal gammopathy and skin signs).[3]
Modality of treatment is strongly guided by clinical classification, 
in particular whether a patient has unicentric or multicentric disease. 
Unicentric type is usually cured by surgical removal of the affected 
lymph nodes or local radiotherapy for sites that are unresectable; 
multicentric disease necessitates systemic therapy.[3] In patients who 
are HIV-negative, multicentric disease is often symptomatic. The 
treatment regimen for the HIV-negative group included: (i) treating 
underlying infection such as HHV-8 (with drugs such as ganciclovir, 
valganciclovir or foscarnet); (ii) decreasing cytokine acceleration with 
tocilizumab (a monoclonal antibody that blocks the IL-6 receptor) or 
corticosteroids (not a popular choice in view of its side-effects); (iii) 
reducing proliferation of B-cells; and (iv) shrinking tumour mass. 
Chemotherapeutic agents in combination or single agents such as 
cyclophosphamide, vinblastine and etoposide can be prescribed for 
systemic disease.[3]
A study by Mylona et al.[7] illustrated that life expectancy in 
multicentric disease appears to have improved, with the fatality 
rate among patients receiving antiretroviral therapy (ART) at 29% 
compared with the fatality rate of 75% among pre-ART patients. 
Another significant finding in their study was that patients on ART 
at the time of diagnosis of MCD had a better immunological profile 
and were less likely to have concurrent Kaposi’s sarcoma than those 
commencing ART after the diagnosis of MCD was made. Despite 
the clinical differences between the patients receiving and those not 
receiving ART, their mortality rates did not vary significantly.[7] The 
administration of monoclonal antibodies also forms part of treatment 
options. Rituximab, an anti-CD20 monoclonal antibody, has been tried 
and a good response has been documented.[1,3,7] The safety of rituximab 
as a single therapeutic agent demands ongoing studies.[3]
Conclusion
Taking into consideration the high prevalence of HIV in South Africa 
(SA), a high clinical index of suspicion should be held when patients 
present with lymphadenopathy accompanied by nonspecic systemic 
signs, as this will increase the likelihood of diagnosing Castleman’s 
disease. A critical aspect is careful examination so that diseases with 
similar clinical presentation are excluded. is case highlights the need 
for lymph node biopsy especially in our SA setting. As described, MCD 
can be associated with serious medical conditions; prompt diagnosis is 
thus essential. More research is needed to establish the optimal therapy 
for this rare disease, particularly in the context of HIV infection. 
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